TY - JOUR
T1 - Medical treatment of mesothelioma
T2 - Anything new?
AU - Takigawa, Nagio
AU - Kiura, Katsuyuki
AU - Kishimoto, Takumi
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2011/8
Y1 - 2011/8
N2 - In the present report, we review the current standard and investigational treatments of malignant pleural mesothelioma (MPM). Several studies have reported the use of gemcitabine and cisplatin as an induction chemotherapy in combination with extrapleural pneumonectomy (EPP) and thoracic radiation in a combined-modality approach for resectable MPM. Since the combination of cisplatin with pemetrexed was applied as the standard first-line regimen for unresectable MPM, the combination as an induction chemotherapy regimen has been proven effective in phase 2 trials. In addition, intensity-modulated radiation therapy and proton therapy have been introduced as new radiation methods into the combined modality. Hyperthermic intraoperative chemotherapy following EPP appears effective with acceptable toxicity. In addition, clinical studies that include molecular targeting agents, immunotherapy, and gene therapy have all been conducted. Thus, although there are numerous hopeful treatments for MPM, the benefits of these regimens remain to be proven in a randomized clinical setting.
AB - In the present report, we review the current standard and investigational treatments of malignant pleural mesothelioma (MPM). Several studies have reported the use of gemcitabine and cisplatin as an induction chemotherapy in combination with extrapleural pneumonectomy (EPP) and thoracic radiation in a combined-modality approach for resectable MPM. Since the combination of cisplatin with pemetrexed was applied as the standard first-line regimen for unresectable MPM, the combination as an induction chemotherapy regimen has been proven effective in phase 2 trials. In addition, intensity-modulated radiation therapy and proton therapy have been introduced as new radiation methods into the combined modality. Hyperthermic intraoperative chemotherapy following EPP appears effective with acceptable toxicity. In addition, clinical studies that include molecular targeting agents, immunotherapy, and gene therapy have all been conducted. Thus, although there are numerous hopeful treatments for MPM, the benefits of these regimens remain to be proven in a randomized clinical setting.
KW - Chemotherapy
KW - Combined modality
KW - Extrapleural pneumonectomy
KW - Gene therapy
KW - Immunotherapy
KW - Malignant pleural mesothelioma
KW - Molecular-targeted therapy
KW - Pemetrexed
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85027954018&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85027954018&partnerID=8YFLogxK
U2 - 10.1007/s11912-011-0172-1
DO - 10.1007/s11912-011-0172-1
M3 - Review article
AN - SCOPUS:85027954018
VL - 13
SP - 265
EP - 271
JO - Current Oncology Reports
JF - Current Oncology Reports
SN - 1523-3790
IS - 4
ER -